{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:07:57Z","timestamp":1790644077966,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.transci.2012.03.022","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T19:46:29Z","timestamp":1334259989000},"page":"315-321","source":"Crossref","is-referenced-by-count":22,"title":["Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases"],"prefix":"10.1016","volume":"46","author":[{"given":"\u00c9lie","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Kafal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.transci.2012.03.022_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2249.2009.03954.x","article-title":"ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: results 2006\u20132008","volume":"157","author":"Gathmann","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.transci.2012.03.022_b0010","unstructured":"Immune Deficiency Foundation (IDF). 1995. Primary immune deficiency diseases in America: 2002. The First National Survey of Patients and Specialists. Towson, MD."},{"issue":"5","key":"10.1016\/j.transci.2012.03.022_b0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10875-007-9105-z","article-title":"Primary immunodeficiency diseases in Australia and New Zealand","volume":"27","author":"Kirkpatrick","year":"2007","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1525-1578(10)60493-X","article-title":"The molecular pathology of primary immunodeficiencies","volume":"6","author":"Lim","year":"2004","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.transci.2012.03.022_b0025","unstructured":"Immune Deficiency Foundation (IDF). 2003. Primary immune deficiency diseases in America: 2002. The Second National Survey of Patients. Towson, MD."},{"issue":"6","key":"10.1016\/j.transci.2012.03.022_b0030","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jpeds.2008.12.020","article-title":"Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation","volume":"154","author":"Urschel","year":"2009","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.transci.2012.03.022_b0035","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.transci.2012.03.022_b0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/0003-4819-93-1-55","article-title":"Immunoglobulin replacement therapy by slow subcutaneous infusion","volume":"93","author":"Berger","year":"1980","journal-title":"Ann. Int. Med."},{"issue":"8760","key":"10.1016\/j.transci.2012.03.022_b0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","article-title":"Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion","volume":"338","author":"Gardulf","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.transci.2012.03.022_b0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/clim.2002.5215","article-title":"Express subcutaneous IgG infusions: decreased time of delivery with maintained safety","volume":"104","author":"Hansen","year":"2002","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies \u2013 a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.transci.2012.03.022_b0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Subcutaneous IgG study group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.transci.2012.03.022_b0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med. J."},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Flebogamma 5% investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"Berger","year":"2004","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.transci.2012.03.022_b0080","doi-asserted-by":"crossref","unstructured":"Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008; 28(4):779\u2013802, viii.","DOI":"10.1016\/j.iac.2008.07.002"},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"US-PID-IGIV 10% \u2013 study group10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency","volume":"26","author":"Church","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.transci.2012.03.022_b0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","article-title":"Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases","volume":"24","author":"Ochs","year":"2004","journal-title":"J. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s10875-006-9031-5","article-title":"Patients\u2019 attitude to subcutaneous immunoglobulin substitution as home therapy","volume":"26","author":"Kittner","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.transci.2012.03.022_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/adc.79.1.48","article-title":"Immunoglobulin replacement treatment by rapid subcutaneous infusion","volume":"79","author":"Gaspar","year":"1998","journal-title":"Arch. Dis. Child."},{"issue":"1\u20134","key":"10.1016\/j.transci.2012.03.022_b0105","first-page":"81","article-title":"Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency","volume":"4","author":"Gardulf","year":"1993","journal-title":"Immunodeficiency"},{"issue":"8946","key":"10.1016\/j.transci.2012.03.022_b0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"Gardulf","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1023\/A:1011051704960","article-title":"Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women","volume":"21","author":"Gardulf","year":"2001","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.transci.2012.03.022_b0120","first-page":"213","article-title":"Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy","volume":"61","author":"Eijkhout","year":"2003","journal-title":"Neth. J. Med."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2006.10.002","article-title":"Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy","volume":"122","author":"Horn","year":"2007","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.transci.2012.03.022_b0130","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr."},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0135","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.transci.2012.03.022_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0145","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10875-008-9180-9","article-title":"Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin","volume":"28","author":"Fasth","year":"2008","journal-title":"J. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.transci.2012.03.022_b0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1365-2648.1995.21050917.x","article-title":"Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients\u2019 experiences of subcutaneous self-infusions and home therapy","volume":"21","author":"Gardulf","year":"1995","journal-title":"J. Adv. Nurs."},{"issue":"6","key":"10.1016\/j.transci.2012.03.022_b0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/2047-783X-15-6-238","article-title":"Vivaglobin Study Group. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency","volume":"15","author":"Hoffmann","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.transci.2012.03.022_b0160","first-page":"163","article-title":"Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations","volume":"2","author":"Wasserman","year":"2008","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","article-title":"Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis","volume":"30","author":"Shapiro","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10198-005-0308-z","article-title":"Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005; (1):24\u20139. Erratum in: Eur J Health Econ. 2005;6(3):243","volume":"9","author":"H\u00f6gy","year":"2008","journal-title":"Eur. J. Health Econ."},{"issue":"2","key":"10.1016\/j.transci.2012.03.022_b0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","article-title":"Study group CEREDIH. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies","volume":"160","author":"Beaut\u00e9","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.transci.2012.03.022_b0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.transci.2012.03.022_b0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1067\/mai.2002.122466","article-title":"Primary immunodeficiency disorders: antibody deficiency","volume":"109","author":"Ballow","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.transci.2012.03.022_b0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2249.2007.03432.x","article-title":"UK Primary Immunodeficiency Network. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review","volume":"149","author":"Wood","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.transci.2012.03.022_b0195","first-page":"771","article-title":"Primary immunodeficiencies","volume":"125","author":"Notarangelo","year":"2010","journal-title":"J Allergy Clin Immunol."}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050212000742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050212000742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:39:29Z","timestamp":1642016369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050212000742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1473050212000742"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2012.03.022","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}